+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 95 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.

Age: 18Years - 80YearsAll GendersPhase 2
107 locations
P

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the safety and tolerability of a second dose of the RSVpreF vaccine given during later pregnancies and to study how long immunity lasts from a single dose administered during a previous pregnancy. The study includes pregnant participants and their unborn babies as well as nonpregnant participants who previously received the vaccine. It is a Phase 3 trial focusing on prevention of RSV infection. Pregnant participants are divided into two groups those with previous antibody data who will receive a second dose of RSVpreF, and those without such data who will be randomly assigned to receive either RSVpreF or a placebo. Infants born to these participants will be monitored for safety and antibody levels up to six months after birth. Nonpregnant participants who received RSVpreF during an earlier pregnancy will have blood samples taken to assess the persistence of their immune response but will not receive any vaccine during this study. Participants will undergo safety assessments including monitoring for local and systemic reactions, adverse events, and serious adverse events after vaccination. Infant safety and antibody levels will also be closely observed. Blood samples will measure neutralizing antibodies at birth and at three and six months. The study involves informed consent and follows participants through pregnancy, birth, and postnatal periods up to six months for infants, with the total study duration extending to February 2028.

Age: 0Years +All GendersPhase 3
97 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
O

Actively Recruiting

Researchers are studying participants with active systemic lupus erythematosus SLE, including those with lupus nephritis, who have not responded adequately to glucocorticoids and at least two immunosuppressant therapies. The aim is to characterize the effectiveness and safety of current standard of care treatments for this condition. This observational study focuses on understanding how these treatments work in real-world settings for patients with active disease. Participants receive treatments based on the current standard of care according to product guidelines, including biologic therapies among other immunosuppressants. The study specifically includes those with active disease confirmed by clinical assessments and positive autoantibodies. Participants with lupus nephritis must have had a recent renal biopsy showing specific active kidney involvement. Treatment and observation continue over several years to evaluate long-term outcomes. During the study, participants undergo evaluations at regular intervals up to 60 months. Researchers assess disease remission, kidney function, disease activity scores, flare frequency, and patient-reported fatigue. Data collection involves clinical assessments, laboratory tests, and questionnaires to measure treatment response and safety. This long-term follow-up provides insight into how well patients maintain remission and respond to standard therapies over time.

Age: 16Years +All Genders
70 locations
C

Actively Recruiting

Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.

Age: 18Years +All GendersPhase 2
331 locations
E

Actively Recruiting

Researchers are evaluating the effects of a medicine called survodutide on adults living with type 2 diabetes who have a body mass index BMI of 23 kgm2 or higher. The study aims to find out whether survodutide helps control blood sugar levels compared to a placebo. This phase III trial includes participants who manage their diabetes with diet and exercise, diabetes tablets, or insulin injections, reflecting different treatment backgrounds. Participants are divided into three parts based on their current diabetes treatment Part A includes those using diet and exercise only, Part B includes those on oral diabetes medications without insulin, and Part C includes those using insulin injections with or without diabetes tablets. Within each part, participants are randomly assigned to one of three groups placebo, low-dose survodutide, or high-dose survodutide. The medicine or placebo is injected under the skin once a week while participants continue their regular diabetes treatment. Over about 14 months, participants attend up to 12 in-person visits and receive at least 9 phone calls for monitoring. Doctors regularly check blood sugar levels using HbA1c tests and other laboratory tests, and monitor overall health and any changes. The main measure is the change in HbA1c from the start to Week 41, while additional outcomes include blood sugar levels, body weight, cholesterol, kidney function, and insulin dose changes. Results will compare survodutide groups with placebo to assess its impact on diabetes management.

Age: 18Years +All GendersPhase 3
101 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations

1-10 of 95

1